Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Viola W. Zhu"'
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 158
Since the discovery of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung carcinoma (NSCLC) in 2007, more than 10 EML4-ALK variants based on the exon breakpoints in EML4 hav
Autor:
Jun Li, Sai-Hong Ignatius Ou, Lu Yang, Yan Yang, Viola W. Zhu, Bing Xia, Misako Nagasaka, Yaning Yang, Jianming Ying, Haiyan Xu, Fei Xu, Yapin Li, Weini Qiu, Guangjian Yang, Yan Wang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 145
To describe the treatment patterns and outcomes of Chinese non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in real-world as EGFR ex20ins consist of a diverse group of muta
Autor:
Yoko Korenaga Fukuda, Jeffrey W. Clark, Shirish M. Gadgeel, Pasi A. Jänne, Patrick M. Forde, Giulia Costanza Leonardi, Sasha Kravets, Viola W. Zhu, Daniel B. Costa, Lynette M. Sholl, Sai-Hong Ignatius Ou, D. Ross Camidge, Rebecca S. Heist, Suzanne E. Dahlberg, Tony Mok, Alexander Drilon, Mark M. Awad, Sinead A. Noonan, Conor E. Steuer
Publikováno v:
Lung Cancer
Objectives Although dramatic responses to MET inhibitors have been reported in patients with MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC), the impact of these treatments on overall survival in this population is unknown. Methods We
Autor:
Jean Cui, Sai-Hong Ignatius Ou, Philip J. Stephens, Vincent A. Miller, Michael E. Goldberg, Alexa B. Schrock, Lee A. Albacker, Viola W. Zhu, Siraj M. Ali
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 108
Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR. Here we report the emergence of novel EGFR solvent front mutations a
Autor:
Siraj M. Ali, Dean Pavlick, Jeffrey C. Milliken, Maria Y. Fernandez-Rocha, Lauren Young, Alexa B. Schrock, Viola W. Zhu, Thomas K. Lee, Sai-Hong Ignatius Ou, Barbara J. Gitlitz
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 106
Development of the acquired ALK G1202R solvent front mutation and small cell lung cancer (SCLC) transformation have both been independently reported as resistance mechanisms to ALK inhibitors in ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC